Anti-leukemic activity of Dasatinib in both p53 wild-type and p53 mutated B malignant cells

Raffaella Bosco, Marco Rabusin, Rebecca Voltan, Claudio Celeghini, Federica Corallini, Silvano Capitani, Paola Secchiero

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The multi-kinase inhibitor Dasatinib induced a variable but significant decrease of viability in both p53 wild-type (EHEB, JVM-2, JVM-3) and p53 mutated (MEC-1, MEC-2, BJAB) prolymphocytic B leukemic cells, due to a combination of cell cycle block in G1 and apoptosis. Antibody phospho-kinase array analysis revealed that Dasatinib inhibited the phosphorylation of various kinases, including ERK1/2 and p38/MAPK as well as of STAT3 transcription factors, in both p53 wild-type and p53 mutated cells. Therefore, Dasatinib might offer a novel therapeutic strategy not only for p53 wild-type, but also for p53 mutated B malignancies that have the worst prognosis and urgently need innovative therapeutic approaches.

Original languageEnglish
Pages (from-to)417-422
Number of pages6
JournalInvestigational New Drugs
Volume30
Issue number1
DOIs
Publication statusPublished - Feb 2012

Fingerprint

Phosphotransferases
STAT3 Transcription Factor
Mitogen-Activated Protein Kinase 3
p38 Mitogen-Activated Protein Kinases
Cell Cycle
Phosphorylation
Apoptosis
Antibodies
Therapeutics
Dasatinib
Neoplasms

Keywords

  • Dasatinib
  • Leukemic cells
  • p53

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Oncology

Cite this

Anti-leukemic activity of Dasatinib in both p53 wild-type and p53 mutated B malignant cells. / Bosco, Raffaella; Rabusin, Marco; Voltan, Rebecca; Celeghini, Claudio; Corallini, Federica; Capitani, Silvano; Secchiero, Paola.

In: Investigational New Drugs, Vol. 30, No. 1, 02.2012, p. 417-422.

Research output: Contribution to journalArticle

Bosco, R, Rabusin, M, Voltan, R, Celeghini, C, Corallini, F, Capitani, S & Secchiero, P 2012, 'Anti-leukemic activity of Dasatinib in both p53 wild-type and p53 mutated B malignant cells', Investigational New Drugs, vol. 30, no. 1, pp. 417-422. https://doi.org/10.1007/s10637-010-9564-6
Bosco, Raffaella ; Rabusin, Marco ; Voltan, Rebecca ; Celeghini, Claudio ; Corallini, Federica ; Capitani, Silvano ; Secchiero, Paola. / Anti-leukemic activity of Dasatinib in both p53 wild-type and p53 mutated B malignant cells. In: Investigational New Drugs. 2012 ; Vol. 30, No. 1. pp. 417-422.
@article{b18280b8fc474642a28c31605de6f141,
title = "Anti-leukemic activity of Dasatinib in both p53 wild-type and p53 mutated B malignant cells",
abstract = "The multi-kinase inhibitor Dasatinib induced a variable but significant decrease of viability in both p53 wild-type (EHEB, JVM-2, JVM-3) and p53 mutated (MEC-1, MEC-2, BJAB) prolymphocytic B leukemic cells, due to a combination of cell cycle block in G1 and apoptosis. Antibody phospho-kinase array analysis revealed that Dasatinib inhibited the phosphorylation of various kinases, including ERK1/2 and p38/MAPK as well as of STAT3 transcription factors, in both p53 wild-type and p53 mutated cells. Therefore, Dasatinib might offer a novel therapeutic strategy not only for p53 wild-type, but also for p53 mutated B malignancies that have the worst prognosis and urgently need innovative therapeutic approaches.",
keywords = "Dasatinib, Leukemic cells, p53",
author = "Raffaella Bosco and Marco Rabusin and Rebecca Voltan and Claudio Celeghini and Federica Corallini and Silvano Capitani and Paola Secchiero",
year = "2012",
month = "2",
doi = "10.1007/s10637-010-9564-6",
language = "English",
volume = "30",
pages = "417--422",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "1",

}

TY - JOUR

T1 - Anti-leukemic activity of Dasatinib in both p53 wild-type and p53 mutated B malignant cells

AU - Bosco, Raffaella

AU - Rabusin, Marco

AU - Voltan, Rebecca

AU - Celeghini, Claudio

AU - Corallini, Federica

AU - Capitani, Silvano

AU - Secchiero, Paola

PY - 2012/2

Y1 - 2012/2

N2 - The multi-kinase inhibitor Dasatinib induced a variable but significant decrease of viability in both p53 wild-type (EHEB, JVM-2, JVM-3) and p53 mutated (MEC-1, MEC-2, BJAB) prolymphocytic B leukemic cells, due to a combination of cell cycle block in G1 and apoptosis. Antibody phospho-kinase array analysis revealed that Dasatinib inhibited the phosphorylation of various kinases, including ERK1/2 and p38/MAPK as well as of STAT3 transcription factors, in both p53 wild-type and p53 mutated cells. Therefore, Dasatinib might offer a novel therapeutic strategy not only for p53 wild-type, but also for p53 mutated B malignancies that have the worst prognosis and urgently need innovative therapeutic approaches.

AB - The multi-kinase inhibitor Dasatinib induced a variable but significant decrease of viability in both p53 wild-type (EHEB, JVM-2, JVM-3) and p53 mutated (MEC-1, MEC-2, BJAB) prolymphocytic B leukemic cells, due to a combination of cell cycle block in G1 and apoptosis. Antibody phospho-kinase array analysis revealed that Dasatinib inhibited the phosphorylation of various kinases, including ERK1/2 and p38/MAPK as well as of STAT3 transcription factors, in both p53 wild-type and p53 mutated cells. Therefore, Dasatinib might offer a novel therapeutic strategy not only for p53 wild-type, but also for p53 mutated B malignancies that have the worst prognosis and urgently need innovative therapeutic approaches.

KW - Dasatinib

KW - Leukemic cells

KW - p53

UR - http://www.scopus.com/inward/record.url?scp=84856551239&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856551239&partnerID=8YFLogxK

U2 - 10.1007/s10637-010-9564-6

DO - 10.1007/s10637-010-9564-6

M3 - Article

VL - 30

SP - 417

EP - 422

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 1

ER -